KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH5 | Potassium voltage-gated channel, subfamily H (eag-related), member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH7 | Potassium voltage-gated channel, subfamily H (eag-related), member 7 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
KCNH8 | Potassium voltage-gated channel, subfamily H (eag-related), member 8 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK1 | Potassium channel, subfamily K, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCNK10 | Potassium channel, subfamily K, member 10 | Predicted membrane proteins
| | | | | Tissue enhanced |
KCNK13 | Potassium channel, subfamily K, member 13 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK16 | Potassium channel, subfamily K, member 16 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNK17 | Potassium channel, subfamily K, member 17 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK18 | Potassium channel, subfamily K, member 18 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNK2 | Potassium channel, subfamily K, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK5 | Potassium channel, subfamily K, member 5 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNMA1 | Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNQ4 | Potassium voltage-gated channel, KQT-like subfamily, member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNS2 | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNS3 | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNT1 | Potassium channel, subfamily T, member 1 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNT2 | Potassium channel, subfamily T, member 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KIAA0195 | KIAA0195 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
LMBRD1 | LMBR1 domain containing 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
LPPR1 | Lipid phosphate phosphatase-related protein type 1 | Predicted membrane proteins
| | | | | Group enriched |
LPPR3 | Hsa-mir-3187 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
LPPR4 | Lipid phosphate phosphatase-related protein type 4 | Enzymes Predicted membrane proteins
| | | | | Tissue enriched |
LPPR5 | Lipid phosphate phosphatase-related protein type 5 | Predicted membrane proteins
| | | | | Group enriched |
MBOAT7 | Membrane bound O-acyltransferase domain containing 7 | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
MCOLN1 | Mucolipin 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Expressed in all |
MCOLN2 | Mucolipin 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
MCOLN3 | Mucolipin 3 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
MFSD7 | Major facilitator superfamily domain containing 7 | Predicted membrane proteins
| | | | | Mixed |
MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MYADM | Myeloid-associated differentiation marker | Predicted membrane proteins Transporters
| | | | | Expressed in all |
NIPAL3 | NIPA-like domain containing 3 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
NOX1 | NADPH oxidase 1 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
NOX4 | NADPH oxidase 4 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | Predicted membrane proteins Transporters
| | | | | Group enriched |
NPC1 | Niemann-Pick disease, type C1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
OCSTAMP | Osteoclast stimulatory transmembrane protein | Predicted membrane proteins
| | | | | Not detected |
OPN4 | Opsin 4 | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
OPRK1 | Opioid receptor, kappa 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
OR10J3 | Olfactory receptor, family 10, subfamily J, member 3 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
OR52B1P | Olfactory receptor, family 52, subfamily B, member 1 pseudogene | Predicted membrane proteins
| | | | | Not detected |
OR56B3P | Olfactory receptor, family 56, subfamily B, member 3 pseudogene | Predicted membrane proteins
| | | | | Not detected |
PAQR3 | Progestin and adipoQ receptor family member III | Predicted membrane proteins
| | | | | Expressed in all |
PCNXL4 | Pecanex-like 4 (Drosophila) | Predicted membrane proteins
| | | | | Expressed in all |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |